profile M8 system takes only20minutessystem to takes identify andquantify as adrop (5–50µl)ofblood, saliva,serumorurine, the material steps. Usingaslittlestarting acid–extraction andnucleic ing thetraditionalsample-preparation qPCR testing method by eliminat it into a one-step Coyote simplifiedthemulti-step process and turned areof the number of DNA copies as they generated. system. to power the casethatcontains abattery carry-size inweight—and kilograms fitinasmall,two hand- to solutions areucts, the lab-in-a-box portable—one fever all andotherpathogens.of Coyote’s Like prod as ‘lab-in-a-box’, for ofEbola, dengue thedetection quantitative PCR(qPCR)-based solutions, referred to Coyote were of miniaturized, a series integrated, The first PCR-based diagnostic tools developed by quantification on-site Rapid Li,Coyote’sSabrina CEO. in the world,” testing to everyone high-quality said level andprovidenostics to thenext accessto this diseases (e.g., viruses). Ebola andZika chlamydia and emerging and gonorrhea) infectious women’spolymorphisms), healthissues(e.g., HPV, (e.g., and quantitation of single-nucleotide detection of applicationssuchascancerpatientstratification need ofefficientPCR-baseddiagnostics for avariety withothercompaniesororganizations in partner diagnostics challenges. developing innovative PCR solutions to address new and itcontinuesto shapethecompany’s strategy for PCRreagents anddevices, ization oftop-of-the-line a reputation for thedevelopment andcommercial years, and inwhichitdeveloped asolidR&Dcapability This philosophy guidedCoyote through itsfirstfive to provide real-time results andpatients. to doctors timepossible intheshortest the pointofcare (POC) and ultimately allow for at thetests to beperformed theprocessPCR-based diagnostics thatmake simpler has strived to design andmanufacture solutionsfor equipment andhighlytrainedpersonnel. requiresbut theirimplementationoften complex gene. Today, sophisticated PCR-basedtests exist, very a target pieceofnucleicacid—thedisease-related inexpensive method billions to of copies of make (PCR),asimpleandthe polymerasechainreaction technologies detection decades. is Oneofthekey related genes, has evolved rapidly over the past two the identificationofspecificpathogens or ofdisease- ofdisease, detection whetherbasedonMolecular diseases toinfectious profiling cancer—for healthcare providers andpatients globally. molecular diagnostics instruments that testing provide solutions—from detecting point-of-care Coyote Biosciences hasdeveloped arange ofminiaturized, and battery-powered portable Molecular diagnostics in abox www.coyotebio.com Coyote Bioscience Co., Ltd. qPCR is a variation ofPCRthat reliesqPCR isavariation onmonitoring “Our goalisto technologically moleculardiag take Coyote to is expanding its offerings and looking Since itsestablishmentin2009,Coyote Biosciences | April 2016| |April nature.com/medtechdealmakers - - - - (WHO) Emergency Quality Assurance Mechanisms Quality Emergency (WHO) included amongthe World HealthOrganization’s ofemergingdetection diseases. As aresult, potential usesisthe oneofitsprincipal tion can be rapidly deployed to any geographic area. forming accurate moleculardetec andcost-effective platforms, Coyote’sportable uniquesolutionfor per andhighly With battery-powered itsself-contained, Emerging diseases and Zika CTO. Coyote’s of thisyear withPOCconsumables,” Ching, saidJesus dPCR-based diagnostic platforms inthe secondhalf solutionforsent alow-cost clientsworldwide. Coyote’s qPCRplatforms, willrepre thedPCR device andrapidlydeployable. Andjustlike is self-contained sample. ing theoriginal numberoftarget moleculesinthe with thenumberofpositive readouts represent either positive ornegative for the target molecule, subsamplewillbe the outputsignal isbinary—any copy or no copies of the target nucleic acid. After PCR, subsamples oftheoriginal volume containeitherone dPCR,samplesare dilutedIn to apointwhere small (dPCR), anabsolute quantitative ofPCR. variation in development atCoyote is basedondigital PCR deployment. an idealsolutionfor fastmedicalscreening andPOC arguably thesimplestoneonmarket—affords target nucleicacids. This simplifiedqPCRplatform— applications. current andfuture moleculardiagnostics for flexibility andadaptability awiderange of qPCRplatformself-contained affords high Figure 1: The Coyote miniaturized,and portable In 2015,Coyote’sIn Real Mini8 Time PCRsystem was “Coyote will be introducing next-generation, Coyote format that isdeveloping dPCRinaportable A secondgenerationofinstrumentscurrently PCR platformsPCR Assays/Tests Emergenc Pandemics Endemics Emerging

y disease

response

Infectious Gastrointestinal Pediatrics Women’s digital PCR digital

health disease s ample-t

Companion SNP Liquid Oncology Integrated

platforms o -a biopsies nswer

POC consumables

- - - - ADVERTISER RETAINS FORCONTENTADVERTISER SOLERESPONSIBILITY eral screening of the Zika virus in China based on the virusinChinabasedonthe eral screening oftheZika implemented asolutionfor the diagnosis andgen Center for Disease Control and Prevention, Coyote inclosecollaboration withtheChinese working thiscase, of itsplatform. In andadaptability versatility offered Coyote anotherchanceto demonstrate the blood within20minutes. a molecular diagnosis of this disease from adrop of has developed agenesensor, to obtain InstantGene, for Ebolavirustesting Sincethen,Coyote inAfrica. viding high-quality moleculartesting to everyone.”viding high-quality institutions thatare aligned withourvisiononpro collaborating orcodeveloping withcompaniesor the company’s products. dealsto commercializeor nationaldistribution any of collaborate test on a new or application, to regional from codevelopment agreementsopportunities, to form ofitsPCRplatforms andtesting kits. deployment ofneededanalyticalcapabilitiesinthe atool for therapiddevelopment andtial partners routine healthmonitoring, Coyote offers itspoten of POC molecular diagnostics forbuilding a network orWhether reacting to apublichealthemergency PCR Partnering the spread ofthevirus. sion withtheBraziliangovernment to helpprevent inBrazilisunderdiscus andqPCRdevices the test kit applicationof of2016.Immediate the secondquarter WHO prequalification program willbesubmitted in applications for registration withtheUSFDA andthe Chinese Food andDrugAdministration (FDA), and company’s qPCRsystem. The recent virus worldwide outbreak of the Zika contact According to Li, “Coyote is interested inpartnering, ofpartnership Coyote avariety willentertain is underreview by the virusdiagnostic kit The Zika Email: Email: Tel: +1-650-528-2199 Campbell, California, USA Tel: 10 +86 6297 7520 China Beijing, Coyote Bioscience Co., Ltd. CEO Li, Sabrina [email protected] ADVERTISEMENT FEATUREADVERTISEMENT - - - -